AstraZeneca Pharma India reported 30% revenue growth to ₹682.8 Cr, with ₹51 Cr profit before tax.

Performance was driven by core therapy areas.

The company strengthened its portfolio with key regulatory approvals and strategic initiatives like the Telangana AI-enabled lung cancer screening MoU.